Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
28.01.25
/
50%
€12.20
Target price
28.01.26
€17.25
Performance (%)
-61.48%
End price
29.01.26
€4.70
Summary
This prediction ended on 29.01.26 with a price of €4.70. Massive losses of -61.48% were the result for the BUY prediction by The_Goldman_Sachs_Gr. The_Goldman_Sachs_Gr has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | 14.815% | 14.815% | -36.642% |
| iShares Core DAX® | 0,79 % | 1,97 % | 13,39 % |
| iShares Nasdaq 100 | 4,23 % | 4,34 % | 39,72 % |
| iShares Nikkei 225® | 3,29 % | 6,99 % | 49,89 % |
| iShares S&P 500 | 2,50 % | 2,76 % | 30,23 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten